Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia

Elias J. Jabbour, Timothy P. Hughes, Jorge E. Cortés, Hagop M. Kantarjian, Andreas Hochhaus

Research output: Contribution to journalReview article

22 Scopus citations


Despite vast improvements in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase (CP), advanced stages of CML, accelerated phase or blast crisis, remain notoriously difficult to treat. Treatments that are highly effective against CML-CP produce disappointing results against advanced disease. Therefore, a primary goal of therapy should be to maintain patients in CP for as long as possible, by (1) striving for deep, early molecular response to treatment; (2) using tyrosine kinase inhibitors that lower risk of disease progression; and (3) more closely observing patients who demonstrate cytogenetic risk factors at diagnosis or during treatment.

Original languageEnglish (US)
Pages (from-to)1451-1462
Number of pages12
JournalLeukemia and Lymphoma
Issue number7
StatePublished - Jul 2014
Externally publishedYes



  • Drug resistance
  • Myeloid leukemias and dysplasias
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this